$TGTX upturn Pr $6.34 TG Therapeutics Announces
Post# of 99221
Posted On: 08/28/2016 8:07:58 PM
$TGTX upturn Pr $6.34
TG Therapeutics Announces Orphan Drug Designation
for TG-1101 for the Treatment of Neuromyelitis Optica
and Neuromyelitis Optica Spectrum Disorder
Website
Float 26.82M
% Held by Insiders 49.75%
% Held by Institutions 1 35.10%
Shares Short 7.24M
Short Ratio 22.93
Short % of Float 24.14%
Shares Short (prior month) 7.54M
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a novel glycol engineered monoclonal antibody that targets a epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkins lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop the inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4); and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101; Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; and Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology. It also has a collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. is headquartered in New York, New York.
TG Therapeutics Announces Orphan Drug Designation
for TG-1101 for the Treatment of Neuromyelitis Optica
and Neuromyelitis Optica Spectrum Disorder
Website
Float 26.82M
% Held by Insiders 49.75%
% Held by Institutions 1 35.10%
Shares Short 7.24M
Short Ratio 22.93
Short % of Float 24.14%
Shares Short (prior month) 7.54M
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a novel glycol engineered monoclonal antibody that targets a epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkins lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop the inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4); and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101; Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; and Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology. It also has a collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. is headquartered in New York, New York.
(0)
(0)